Bluejay Diagnostics wraps up enrollment in pivotal sepsis trial ahead of schedule

summarizeSummary

Bluejay Diagnostics has completed enrollment in its pivotal SYMON-II sepsis trial ahead of schedule, marking a key step toward FDA clearance for its Symphony IL-6 rapid diagnostic platform.

check_boxKey Events · Product Development and Regulatory · BJDX

• Pivotal Trial Enrollment Completed

  The SYMON-II multicenter clinical validation study enrolled 750 patients ahead of schedule, evaluating the Symphony IL-6 test for early assessment of 28-day sepsis mortality risk.

• Preliminary Mortality Rate of 17%

  An approximately 17% 28-day mortality rate in the enrolled population provides a clinically meaningful dataset for assessing IL-6's prognostic utility.

• Regulatory Path Forward

  Study results will support a planned 510(k) application to the FDA; data cleaning, analysis, and clinical reporting are expected over the coming months.

• Cash Runway Context

  As of March 31, 2026, the company held $3.7M in cash, with a going-concern warning and cash expected to last only through Q3 2026 — positive trial data is critical to attracting funding or partnership.

auto_awesomeAnalysis · BJDX · Industrial Applications And Services

Enrollment in the SYMON-II pivotal clinical trial for the Symphony IL-6 sepsis test has been completed ahead of plan, with 750 patients now enrolled. For a company facing a going-concern warning and limited cash runway, this operational milestone is critical — positive trial data could unlock regulatory clearance and commercialization, directly mitigating the survival risk. The enrolled population's preliminary 28-day mortality rate of approximately 17% yields a robust dataset for evaluating the test's prognostic utility. Results are expected in the coming months and will be central to the FDA submission strategy.